IUGNF - Imugene thrilled as first patient dosed in Phase 1 OASIS trial
(NewsDirect)
Imugene Ltd (ASX:IMU,OTC:IUGNF) CEO Leslie Chong tells Proactive the company has marked amilestone with the start of its Phase 1 clinical trial foronCARlytics, a CD19 oncolytic virotherapy drug candidate. The trial,known as OASIS (Oncolytic Assessment and Safety in Solid Tumours),represents a world-first in clinical research, combining CD19oncolytic virotherapy with a CD19 targeting bispecific monoclonalantibody, blinatumomab (Blincyto® Amgen). The primary objective ofthe OASIS trial is to assess the safety and tolerability ofonCARlytics (CF33-CD19) when administered intravenously orintratumorally in combination with blinatumomab.
Chong said: “This is amilestone we’ve been eagerly anticipating, given the encouragingsigns we have seen from the pre-clinical work performed to date.
“We believeonCARlytics may provide a new solution for clinicians treating solidtumours that have previously been untreatable using CD19-targetingbiological drugs, and we hope our technology can bring much neededrelief to patients in want of new treatments.
“I am particularly pleased with the speed at which our teamdrove the pre-clinical data from a novel therapy, into a Phase 1 trialin a little over two years, and reflects the enthusiasm for thispromising therapy, from all involved.”
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.